Drug delivery composition
Acid-resistant cells from the Cyanidiophyceae class encapsulate drugs in bag-like membrane structures to overcome stomach degradation, enabling efficient intestinal delivery and immunity enhancement in livestock.
Patent Information
- Application Number
- JP2024135405
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-03-29
- Filing Date
- 2024-08-14
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing drug delivery methods, particularly for livestock, face challenges in delivering drugs to the intestines without degradation, as they are susceptible to enzymatic and acidic conditions in the stomach, and current techniques are costly for large-scale applications.
Development of acid-resistant cells, such as those from the Cyanidiophyceae class, encapsulating drugs in bag-like membrane structures to protect them from stomach acids and enzymes, allowing targeted delivery to the intestines.
The acid-resistant cells effectively deliver drugs to the intestines, enhancing intestinal immunity and potentially activating mucosal and systemic immunity, while being cost-effective for large-scale livestock applications.
Smart Images

Figure 2024167241000005 
Figure 2024167241000006 
Figure 2024167241000007
Abstract
Description
[Technical field]
[0001] The present invention relates to a drug delivery composition, and also to an acid-tolerant cell and a drug carrier that can be used in the drug delivery composition, as well as a method for producing the acid-tolerant cell. This application claims priority based on Japanese Patent Application No. 2019-069029, filed on March 29, 2019, the contents of which are incorporated herein by reference. [Background technology]
[0002] In animals with a digestive tract, including humans, what is ingested through the mouth is sent to the stomach through the esophagus. For example, when a drug is orally administered, there is a high possibility that the drug will be enzymatically decomposed in the stomach, especially if the drug is mainly composed of peptides or proteins. In addition, since the inside of the stomach is highly acidic, even drugs that are low molecular weight compounds may be non-enzymatically decomposed in the stomach. In addition, even if an acidic compound is intended to be absorbed in the intestine, it may be absorbed in the stomach. For this reason, oral administration using a capsule that does not dissolve in the stomach but dissolves in the intestine is useful.
[0003] Known methods for delivering drugs to the intestine include a technology called bilosome (Non-Patent Document 1), which utilizes the property that lipids incorporating protein B are stable in the stomach; a rice vaccine (Non-Patent Document 2), which utilizes the resistance of protein bodies, which are organelles in rice cells, to digestive enzymes; and a spore vaccine (Non-Patent Document 3), which uses spores that are resistant to digestive enzymes, temperature changes, and pH changes.
[0004] As an industrial oral vaccine, those using yeast are known. For example, Patent Document 1 describes an oral vaccine in which an antigenic protein is expressed in yeast cells. Patent Document 1 shows that freeze-drying yeast cells prevents digestion in the stomach and jejunum and results in digestive decomposition in the ileum, but the release of antigenic proteins from yeast depends on the function of digestive enzymes in the small intestine. Patent Document 2 suggests that immunity is induced by transmucosal / oral administration of a yeast strain incorporating an exogenous gene, but also describes that the yeast-derived protein used is antigenic. [Prior art documents] [Patent documents]
[0005] [Patent Document 1] International Publication No. 2006 / 028214 [Patent Document 2] Special Publication No. 2012-508697 [Non-patent literature]
[0006] [Non-Patent Document 1] Mann JF et al., Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1 / Th2 bias in the immune response and protection against infection. Vaccine. 2009 Jun 2;27(27):3643-9. [Non-Patent Document 2] Nochi T et al., Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. Proc Natl Acad Sci US A. 2007Jun 26;104(26):10986-91. [Non-Patent Document 3] Huang JM et al., Mucosal delivery of antigens using adsorption to bacterial spores. Vaccine. 2010 Jan 22;28(4):1021-30. Summary of the Invention [Problem to be solved by the invention]
[0007] In the livestock industry, when an infectious disease occurs, it is difficult to suppress the spread of the disease, and sometimes a large number of livestock are slaughtered. Some infectious diseases are said to be preventable by intestinal immunity, and the development of a technology to establish immunity against pathogens in the intestines of livestock animals is an urgent task. In addition, by imparting intestinal immunity, it is possible to impart other mucosal immunity and systemic immunity. Therefore, there is a demand for the development of an enteric composition that can deliver a vaccine directly to the intestine by oral administration. However, the technologies described in Non-Patent Documents 1 to 3 have a problem in terms of cost when used in the livestock industry.
[0008] Therefore, an objective of the present invention is to provide a novel drug delivery composition capable of delivering a drug to the intestine, acid-resistant cells and drug carriers that can be used in the drug delivery composition, and a method for producing the acid-resistant cells. [Means for solving the problem]
[0009] The present invention includes the following aspects. [1] A drug delivery composition comprising acid-resistant cells encapsulating a drug. [2] The drug delivery composition described in [1], wherein the drug is localized in a sac-like membrane structure possessed by the acid-resistant cells. [3] The drug delivery composition described in [2], wherein the sac-like membrane structure is at least one selected from the group consisting of exogenous liposomes and cell organelles. [4] The drug delivery composition described in [3], wherein the organelle is at least one selected from the group consisting of mitochondria, chloroplasts, endoplasmic reticulum, vacuoles, cell nuclei, peroxisomes, and Golgi apparatus. [5] The drug delivery composition according to any one of [1] to [4], wherein the drug is at least one selected from the group consisting of low molecular weight compounds, peptides, proteins, and nucleic acids. [6] The drug delivery composition according to any one of [1] to [5], wherein the drug is a drug that acts in the intestine. [7] The drug delivery composition according to any one of [1] to [6], wherein the drug is an immunogenic drug. [8] The drug delivery composition according to any one of [1] to [7], wherein the acid-resistant cells are cells that undergo cell rupture at a pH of 7 or higher. [9] The drug delivery composition according to any one of [1] to [8], wherein the acid-resistant cells are cells resistant to acidic conditions of pH 1 to 3.
[10] The drug delivery composition according to any one of [1] to [9], wherein the acid-tolerant cells are cells of an alga belonging to the Cyanidiophyceae family.
[11] A feed containing the drug delivery composition described in any one of [1] to
[10] .
[12] A pharmaceutical comprising the drug delivery composition described in any one of [1] to
[10] .
[13] A food product comprising the drug delivery composition described in any one of [1] to
[10] .
[14] Acid-resistant cells harboring drugs.
[15] The acid-resistant cell according to
[14] , wherein the drug is localized in a sac-like membrane structure possessed by the acid-resistant cell.
[16] The acid-resistant cell according to
[14] , wherein the drug is localized outside a sac-like membrane structure possessed by the acid-resistant cell.
[17] The acid-resistant cell according to any one of
[14] to
[16] , wherein the drug is at least one selected from the group consisting of a low molecular weight compound, a peptide, a protein, and a nucleic acid.
[18] A method for producing acid-tolerant cells according to
[15] , comprising the step of introducing into acid-tolerant cells a gene encoding a fusion protein comprising a peptide or protein as a drug and a peptide or protein localized to a cell membrane or organelle.
[0010] The present invention also includes the following aspects.
[19] Drug carriers containing acid-resistant cells.
[20] The drug carrier described in
[19] , wherein the acid-resistant cells are cells that undergo cell rupture at a pH of 7 or higher.
[21] The drug carrier described in
[19] or
[20] , wherein the acid-resistant cells are cells that are resistant to acidic conditions of pH 1 to 3.
[22] The drug carrier described in any one of
[19] to
[21] , wherein the acid-tolerant cells are cells of an alga belonging to the Cyanidiophyceae family.
[23] A drug capsule comprising a drug carrier described in any one of
[19] to
[22] and a drug encapsulated therein.
[24] The drug carrier described in
[23] , wherein the drug is localized in a sac-like membrane structure possessed by the acid-resistant cells.
[0011] The present invention also includes the following aspects.
[25] Acid-resistant cells containing exogenous substances.
[26] The acid-tolerant cell according to
[25] , wherein the exogenous substance is localized in a sac-like membrane structure possessed by the acid-tolerant cell.
[27] The acid-tolerant cell according to
[25] or
[26] , wherein the exogenous substance is at least one selected from the group consisting of low molecular weight compounds, peptides, proteins, nucleic acids, and synthetic polymer compounds.
[28] The acid-tolerant cell according to any one of
[25] to
[27] , wherein the exogenous substance is a substance that acts in the intestine.
[29] The acid-tolerant cell according to any one of
[25] to
[28] , wherein the exogenous substance is an immunogenic substance.
[30] The acid-tolerant cell according to any one of
[26] to
[29] , wherein the sac-like membrane structure is at least one selected from the group consisting of an exogenous liposome, a cell membrane, and a cell organelle.
[31] The acid-tolerant cell according to
[30] , wherein the organelle is at least one selected from the group consisting of mitochondria, chloroplasts, endoplasmic reticulum, vacuoles, cell nuclei, peroxisomes, and Golgi apparatus.
[32] The acid-tolerant cell according to any one of
[25] to
[31] , wherein the acid-tolerant cell is a cell that undergoes cell rupture at a pH of 7 or higher.
[33] The acid-tolerant cell according to any one of
[25] to
[32] , wherein the acid-tolerant cell is a cell that is resistant to acidic conditions of pH 1 to 3.
[34] The acidotolerant cell according to any one of
[25] to
[33] , which is a cell of an alga belonging to the Cyanidiophyceae family.
[35] A feed comprising the acid-tolerant cells according to any one of
[25] to
[34] .
[36] A pharmaceutical comprising the acid-resistant cells described in any one of
[25] to
[34] .
[37] A food product containing the acid-tolerant cells described in any one of
[25] to
[34] .
[38] A method for administering an exogenous substance, comprising orally administering the acid-resistant cell according to any one of
[25] to
[34] to a subject.
[39] A method for raising an animal, comprising feeding the animal with the acid-resistant cell according to any one of
[25] to
[34] .
[40] A method for conferring intestinal immunity, comprising orally administering the acid-resistant cell described in any one of
[25] to
[34] . Effect of the Invention
[0012] According to the present invention, it is possible to provide a novel drug delivery composition capable of delivering a drug to the intestine, acid-resistant cells and drug carriers that can be used in the drug delivery composition, and a method for producing the acid-resistant cells. [Brief description of the drawings]
[0013] [Figure 1] 1 shows the results of immunoblotting using anti-GFP antibody for GAPDH-GP-sfGFP expressing strains cultured in the presence or absence of MG-132. In the figure, the arrowhead indicates the band of GAPDH-GP-sfGFP protein. [Diagram 2]Fluorescence microscopy images of GAPDH-GP-sfGFP expressing strains. (A) PC: phase contrast image showing cell outline; (B) Chl: autofluorescence image of chloroplasts; (C) sfGFP: fluorescence image of sfGFP. [Diagram 3] FIG. 2 shows the structure of the DNA fragment used to prepare the Chl-TP-3HA-GP-Co1 expression strain in Example 2. [Figure 4] 1 shows the results of immunoblotting using anti-HA antibody for Chl-TP-3HA-GP-Co1 expressing strains cultured in the presence or absence of MG-132. In the figure, the arrowhead indicates the band of Chl-TP-3HA-GP-Co1 protein. [Diagram 5] Fluorescence microscopy images of the Chl-TP-3HA-GP-Co1 expressing line. (A) PC: phase contrast microscopy image showing the outline of the cells; (B) Chl: autofluorescence image of chloroplasts; (C) sfGFP: immunofluorescence staining image with anti-HA antibody. [Figure 6] This figure shows the results of evaluating anti-GP protein antibody production by immunoblotting in mice administered a suspension of the sfGFP expression strain (control suspension administration group), a suspension of the Chl-TP-3HA-GP-Co1 expression strain (suspension administration group), or alginic acid solidified feed of the Chl-TP-3HA-GP-Co1 expression strain (alginic acid solidified feed administration group). (A): alginic acid solidified feed administration group; (B) suspension administration group; (C) control suspension administration group. Numbers 1 to 4 indicate individual mouse numbers. [Figure 7] The molecular phylogenetic tree of the algae belonging to the class Polypodium based on the chloroplast ribulose 1,5-bisphosphate carboxylase / oxygenase large subunit gene is shown. Local bootstrap values by the maximum likelihood method (only values 50 or higher are shown, left) and posterior probabilities by the Bayes method (only values 0.95 or higher are shown, right) are shown near each branch. Known species of Cyanidioschyzon melorae are surrounded by dotted lines, and strains YFU3 and HKN1 are surrounded by solid lines. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] [Definition] As used herein, the terms "peptide" and "protein" are used interchangeably to refer to a polymer of amino acids linked by amide bonds. A "peptide" or "protein" may be a polymer of natural amino acids, a polymer of natural and non-natural amino acids (such as chemical analogs or modified derivatives of natural amino acids), or a polymer of non-natural amino acids. Unless otherwise specified, amino acid sequences are written from the N-terminus to the C-terminus. The number of amino acid residues constituting a "peptide" or "protein" is not particularly limited, and an amino acid polymer having two or more amino acid residues is encompassed by the term "peptide" or "protein". In this specification, unless otherwise specified, a polymer having a large number of amino acid residues (e.g., 100 or more amino acid residues) is referred to as a "protein", and a polymer having a small number of amino acid residues (e.g., less than 100 amino acids) is referred to as a "peptide".
[0015] As used herein, the terms "polynucleotide" and "nucleic acid" are used interchangeably and refer to a nucleotide polymer in which nucleotides are linked by phosphodiester bonds. A "polynucleotide" and a "nucleic acid" may be DNA, RNA, or a combination of DNA and RNA. A "polynucleotide" and a "nucleic acid" may be a polymer of natural nucleotides, a polymer of natural nucleotides and non-natural nucleotides (such as analogs of natural nucleotides, nucleotides in which at least one of the base moiety, sugar moiety, and phosphate moiety is modified (e.g., phosphorothioate backbone), etc.), or a polymer of non-natural nucleotides. Unless otherwise specified, the base sequence is written from the 5' to the 3' side.
[0016] As used herein, the term "gene" refers to a polynucleotide that contains at least one open reading frame that encodes a particular protein. A gene can include both exons and introns.
[0017] As used herein, the term "operably linked" with respect to a polynucleotide means that a first base sequence is positioned sufficiently close to a second base sequence that the first base sequence can affect the second base sequence or a region under the control of the second base sequence. For example, a polynucleotide being "operably linked to a promoter" means that the polynucleotide is linked so as to be expressed under the control of the promoter. As used herein, the term "promoter is operable" means that the promoter is capable of causing the expression of a polynucleotide operably linked to the promoter in a cell of a subject. As used herein, the term "expressible state" means that a polynucleotide or gene is in a state in which it can be transcribed in a cell into which the polynucleotide has been introduced. As used herein, the term "expression vector" refers to a vector that contains a target polypeptide and is equipped with a system that enables the target polynucleotide to be expressed in a cell into which the vector has been introduced.
[0018] As used herein, the term "drug delivery composition" refers to a composition used to deliver a drug to any site in a living body (such as an organ, tissue, or disease site).
[0019] As used herein, the term "drug carrier" refers to a carrier used to deliver a drug. The drug carrier may be either organic or inorganic. When the drug carrier is composed of an organic material, the drug carrier may be a cell.
[0020] As used herein, a cell "containing a drug" means that the drug is present within the cell and / or that the drug is present in the cell membrane. When the drug is present within the cell, the drug may be present inside an organelle.
[0021] In this specification, a drug being "localized in a saccular membrane structure" means that the majority of the drug is present inside the target saccular membrane structure (inside the sac) or in the membrane that forms the saccular membrane structure (hereinafter referred to as "saccular membrane"). When a drug is localized in a saccular membrane structure possessed by a cell, it is not necessary for all of the drug encapsulated in the cell to be present inside the saccular membrane structure or in the saccular membrane, and some of the drug may be present outside the saccular membrane structure. When a drug is "localized in a saccular membrane structure", the proportion of the drug present in the saccular structure can be, for example, 50% or more of the total amount of drug encapsulated in the cell, preferably 60% or more, more preferably 70% or more, and even more preferably 80% or more.
[0022] As used herein, the term "small molecular weight compound" refers to a compound with a molecular weight of about 2,000 or less. However, peptides and nucleic acids with a molecular weight of 2,000 or less are not included in the term "small molecular weight compound." As used herein, "synthetic polymer compounds" refer to non-natural compounds with a molecular weight of 2000 or more. "Non-natural compounds" refer to compounds that do not exist in nature. Synthetic polymer compounds include various synthetic polymers (polyolefins, polyesters, polyamides, polyethylene glycols, poly(2-oxazolines), etc.). Artificially chemically synthesized peptides, proteins, and nucleic acids are not included in "synthetic polymer compounds."
[0023] In this specification, the term "exogenous substance" refers to a substance introduced from outside a cell, or a substance produced within a cell by a substance introduced from outside a cell. Specific examples of substances produced within a cell by a substance introduced from outside a cell include the transcription product (mRNA) and translation product (protein) of an exogenous gene in a cell into which the exogenous gene has been introduced; and active metabolites of a prodrug (drugs exhibiting a desired medicinal effect) in a cell into which a prodrug has been introduced. An exogenous substance is a substance that is different from a substance that a cell originally has (an endogenous substance).
[0024] In this specification, the term "drug" refers to a substance that exhibits beneficial activity in a living body. The beneficial activity exhibited by a drug is not particularly limited and includes physiological activity, pharmacological activity, biological activity, and chemical activity useful for diagnosis, etc. For example, the activity may include the pharmacological activity of a compound known as an active ingredient of a pharmaceutical, and the chemical activity or physiological activity of a diagnostic agent administered to the body for use. Examples of the activity include, but are not limited to, immune-inducing activity, immune-stimulating activity, anticancer activity, signal transduction inhibitory activity, signal transduction promoting activity, metabolic antagonist activity, analgesic activity, anti-inflammatory activity, bactericidal activity, antiviral activity, antiallergic activity, enzyme inhibitory activity, contrast effect, and fluorescent activity. The drug may be a compound that releases a compound that exhibits beneficial activity in a living body (so-called prodrug).
[0025] In this specification, the term "pharmaceuticals" includes medical drugs and drugs in the broad sense taken for the treatment or prevention of illness or for health promotion. "Pharmaceuticals" are not limited to those officially registered or used for medical or non-medical purposes. In this specification, the term "food" is used to encompass general foods, health foods, nutritional supplements, health supplements, functional foods, beauty supplements, and supplements.
[0026] As used herein, the term "mutant" refers to a cell line in which a mutation has occurred naturally or artificially in the genome (including the nuclear genome, chloroplast genome, and mitochondrial genome; the same applies below) of the original cell line. The artificial method for causing a mutation in the genome is not particularly limited. Examples of the artificial method include ultraviolet irradiation, radiation irradiation, chemical treatment with nitrous acid, etc.; genetic engineering methods such as gene introduction and genome editing, etc. As used herein, the term "YFU3 mutant" refers to an algae strain in which a mutation has occurred in the genome of the YFU3 strain, and which has both a diploid and a haploid cell morphology. The term "HKN1 mutant" refers to an algae strain in which a mutation has occurred in the genome of the HKN1 strain, and which has both a diploid and a haploid cell morphology.
[0027] In the present specification, the term "closely related species" refers to, for example, a cell line in which the base sequence of the rbcL gene, 18SrRNA gene, or 16sRNA gene has 90% or more identity with the base sequence of the gene of the original organism. When the organism is an alga, the gene to be compared is the rbcL gene or the 18SrRNA gene, preferably the rbcL gene. The identity between the base sequence of the rbcL gene of the original alga and the base sequence of the rbcL gene of the closely related alga is preferably 95% or more, more preferably 97% or more, even more preferably 98% or more, and particularly preferably 99% or more. The base sequence of the rbcL gene of the alga can be obtained by a known method. For example, the base sequence of the rbcL gene of the target alga can be obtained by extracting DNA from the target algae cells by a known method, amplifying a DNA fragment of the rbcL gene by PCR or the like, and analyzing the base sequence of the amplified DNA fragment with a DNA sequencer.
[0028] Drug Delivery Compositions In one embodiment, the present invention provides a drug delivery composition comprising an acid-resistant cell encapsulating a drug. In a preferred embodiment, the drug is localized in a sac-like membrane structure of the acid-resistant cell.
[0029] <Acid-resistant cells> In the present specification, the term "acid-tolerant cells" refers to cells that are resistant to acidic conditions. Specific examples of the acidic conditions include pH conditions of pH 1 to 3. Acid-tolerant cells are preferably resistant to pH conditions of pH 1 to 4, and more preferably resistant to pH conditions of pH 1 to 5. The term "resistant to" acidic conditions means that the cells do not rupture and the elution of the cell contents does not occur under acidic conditions.
[0030] The acid-tolerant cells may be living cells or dead cells, but preferably the cells maintain their morphology. The acid-tolerant cells preferably have no damage to the cell membrane and / or its outer membrane, and no elution of the cell contents. When the acid-tolerant cells are living cells, the cells are capable of growing under acidic conditions.
[0031] The type of the acid-tolerant cells is not particularly limited. Examples of the acid-tolerant cells include acid-tolerant algal cells. Preferred examples of such algal cells include cells of microalgae isolated from acidic environments such as acidic hot springs. Specific examples of such microalgae include algae belonging to the Cyanidiophyceae family.
[0032] Taxonomically, the class Cyanidiophyceae is classified into the division Rhodophyta. Three genera, namely Cyanidioschyzon, Cyanidium, and Galdieria, are currently classified into the class Cyanidiophyceae. The acid-tolerant cells may be algae belonging to any of these genera. Whether or not a certain algae belongs to the class Cyanidiophyceae can be determined by, for example, phylogenetic analysis using the base sequence of the 18S rRNA gene or the chloroplast ribulose 1,5-bisphosphate carboxylase / oxygenase large subunit (rbcL) gene. The phylogenetic analysis may be performed by a known method. A molecular phylogenetic tree based on the base sequence of the rbcL gene of algae belonging to the class Cyanidiophyceae is shown in FIG. 7.
[0033] Some algae in the class Polyploidea have both diploid and haploid cell morphologies. A haploid cell morphology can arise from a diploid cell morphology by meiosis. A haploid cell can then give rise to a diploid cell by the union of two haploid cells. It is easier to prepare transformants using recombinant gene technology in haploid cells than in diploid cells. Therefore, as described below, haploid cells can be preferably used when introducing a gene encoding a peptide as a drug into acid-resistant cells. In addition, by using haploid cells to prepare multiple transformants into which any drug-encoding gene has been introduced and crossing these transformants with each other, it is possible to prepare a diploid that has multiple drug-encoding genes and contains multiple drugs.
[0034] Whether an alga is diploid or haploid can be determined by checking the copy number of the same gene locus. In other words, if the copy number of the same gene locus is 1, it is determined to be haploid. It is also possible to determine whether an alga is haploid using a next-generation sequencer or the like. For example, whole genome sequence reads are obtained using a next-generation sequencer or the like, and after assembling these sequence reads, the sequence reads are mapped to the assembled sequence. In diploids, differences in bases for each allele are found in various regions on the genome, but in haploids, such regions are not found because only one allele exists. Alternatively, cells may be stained with a nuclear staining reagent such as DAPI, and compared to cells known to be haploid, cells that exhibit the same fluorescence brightness may be determined to be haploid, and cells that exhibit approximately twice the fluorescence brightness may be determined to be diploid. Alternatively, cells may be stained with a nuclear staining reagent such as DAPI, and compared to cells known to be diploid, cells that exhibit the same fluorescence brightness may be determined to be diploid, and cells that exhibit approximately half the fluorescence brightness may be determined to be haploid.
[0035] In order to rapidly release the drug in the intestine, it is preferable that the acid-resistant cells do not have a strong cell wall. In this specification, "does not have a strong cell wall" means that the cells are ruptured by any of the following cell rupture treatments (A) to (C).
[0036] (A) Cells are suspended in an isotonic solution with a pH of 7 or higher and allowed to stand for one week or more. (B) Cells are suspended in distilled water and allowed to stand for at least 1 minute. (C) The cells are dried and suspended in an isotonic solution with a pH of 7 or higher. In the above (A) to (C), when the cells are cultured cells, before each treatment, the medium may be removed by centrifugation or the like, and the algal cells may be washed with an isotonic solution or the like. In the above (A) and (C), the isotonic solution may be a buffer solution of pH 7 containing 10% sucrose and 20 mM HEPES. In the above (C), the drying treatment may be drying in a refrigerator (4°C), freeze-drying, etc. For the drying treatment, a precipitate of algae cells collected by centrifugation is used. When drying in a refrigerator, the drying treatment time depends on the amount of cells, but is, for example, 3 days or more.
[0037] In addition, whether or not cell rupture has occurred can be determined by centrifuging the cell suspension after the cell rupture treatments (A) to (C) above (1,500×g, 3 minutes) and determining the ratio of the protein amount in the centrifugal supernatant to the total protein amount in the cell suspension. Specifically, cell rupture can be determined to have occurred when the rupture rate calculated by the following formula is 20% or more.
[0038]
number
[0039] Alternatively, cells in the cell suspension may be observed under an optical microscope (e.g., 600x magnification), and cell rupture may be determined to have occurred if the proportion of cells in which rupture has occurred is approximately 10% or more, preferably approximately 20% or more, of the total cells.
[0040] If the cells do not have a strong cell wall, the cell wall is usually not observed under an optical microscope (for example, at a magnification of 600 times). Whether or not the cells burst upon mild hypotonic treatment at a pH of 6 or less does not affect the determination of whether or not the algae does not have a strong cell wall.
[0041] In the above cell rupture treatments (A) and (C), an isotonic solution having a pH of 7 or higher can be used, and therefore, cells that undergo cell rupture in either of the above cell rupture treatments (A) and (C) can be said to be cells that undergo cell rupture at a pH of 7 or higher. In order to rapidly release the drug in the intestine, the acid-resistant cells are preferably cells that undergo cell rupture at a pH of 7 or higher.
[0042] In addition, whether or not the cells will burst under conditions of pH 7 or higher can also be determined by immersing the cells in a buffer solution of pH 7 or higher and observing for about 10 to 30 minutes to confirm whether or not the algal cells burst.
[0043] Examples of acid-tolerant cells having the above characteristics include Cyanidioschyzon merolae, haploid algae belonging to the genus Garderia, and haploid algae belonging to the genus Cyanidium, among other algae belonging to the class Polytrichum. These algae may be isolated from acidic environments such as acidic hot springs, or may be obtained from culture collections. Examples of such culture collections include the Microbial Culture Collection of the National Institute for Environmental Studies (16-2 Onogawa, Tsukuba, Ibaraki, Japan) and the American Type Culture Collection (ATCC; 10801 University Boulevard Manassas, VA 20110 USA).
[0044] Examples of haploid algae belonging to the genus Galdelia include haploid algae of Galdieria sulphuraria and Galdieria partita, as well as haploid algae of related species, mutants, and progenies thereof. For example, diploid algae belonging to the genus Galdelia obtained from a culture collection or the like are cultured until they reach the stationary phase, and then the culture is continued for any period of time, whereby haploid cells appear in the culture medium. The haploid cells may be collected and used as acid-resistant cells.
[0045] Examples of haploid algae belonging to the genus Cyanidium include haploid Cyanidium sp. strain YFU3 (FERM BP-22334) (hereinafter referred to as "YFU3 strain") and haploid Cyanidium sp. strain HKN1 (FERM BP-22333) (hereinafter referred to as "HKN1 strain"), as well as closely related species, mutant strains, and progenies thereof. The YFU3 strain (haploid) is a unicellular red alga isolated from high-temperature acidic water of a hot spring in Yufu City, Oita Prefecture, Japan. The YFU3 strain was deposited at the National Institute of Technology and Evaluation (2-5-8 Kazusa Kamatari, Kisarazu City, Chiba Prefecture, Japan) on May 30, 2017 under the accession number FERM P-22334, and transferred to an international deposit on April 20, 2018 under the accession number FERM BP-22334. The HKN1 strain is a unicellular red alga isolated from high-temperature acidic water of a hot spring in Hakone, Ashigarashimo-gun, Kanagawa Prefecture, Japan. The HKN1 strain (haploid) was deposited at the National Institute of Technology and Evaluation (NITE) Patent Microorganism Depositary under the accession number FERM P-22333 on May 30, 2017, and transferred to an international deposit under the accession number FERM BP-22333 on April 20, 2018.
[0046] Algae belonging to the class Polytrichum can be cultured using a medium for culturing microalgae. The medium is not particularly limited, but examples thereof include inorganic salt mediums containing nitrogen sources, phosphorus sources, trace elements (zinc, boron, cobalt, copper, manganese, molybdenum, iron, etc.). For example, nitrogen sources include ammonium salts, nitrates, nitrites, urea, amines, etc., and phosphorus sources include phosphates, etc. Examples of such media include 2x Allen medium (Allen MB. Arch. Microbiol. 1959 32: 270-277.), M-Allen medium (Minoda A et al. Plant Cell Physiol. 2004 45: 667-71.), MA2 medium (Ohnuma M et al. Plant Cell Physiol. 2008 Jan;49(1):117-20.), etc.
[0047] Algae belonging to the class Polypodium can also be cultured in a medium using acidic hot spring effluent. "Acidic hot spring effluent" refers to acidic effluent discharged from a hot spring facility. The acidic hot spring effluent is not particularly limited, but is preferably pH 1.0 to 4.0, more preferably pH 1.0 to 3.0. "Culture medium using acidic hot spring effluent" refers to a culture medium prepared by adding a nitrogen source, a phosphorus source, trace elements, etc. to acidic hot spring effluent. As a culture medium using acidic hot spring effluent, a culture medium to which a nitrogen source has been added to acidic hot spring effluent is preferable, and a culture medium to which a nitrogen source and a phosphorus source have been added is more preferable (for example, see Hirooka S and Miyagishima SY (2016) Cultivation of Acidophilic Algae Galdieria sulphuraria and Pseudochlorella sp. YKT1 in Media Derived from Acidic Hot Springs. Front Microbiol. Dec 20;7:2022.). Examples of the nitrogen source include ammonium salts (ammonium sulfate, etc.), urea, and nitrates (sodium nitrate, etc.), with ammonium salts and urea being preferred, and ammonium salts being more preferred. Examples of the amount of nitrogen source added include 1 to 50 mM in terms of the amount of nitrogen added. Examples of the amount of nitrogen source added include 5 to 40 mM in terms of the amount of nitrogen added, and more preferably 10 to 30 mM in terms of the amount of nitrogen added. Examples of the phosphorus source include phosphates (potassium dihydrogen phosphate, etc.). Examples of the amount of phosphorus source added include 0.1 to 10 mM in terms of the amount of phosphorus added, and the amount of phosphorus source added is preferably 0.5 to 5 mM in terms of the amount of phosphorus added, and more preferably 1 to 3 mM in terms of the amount of phosphorus added. Algae belonging to the class Polytrichum can also be cultured in a medium using acidic hot spring effluent, so that the acidic hot spring effluent can be effectively utilized, and the algae can be cultured at low cost. When the algae belonging to the class Polytrichum are those belonging to the genus Garderia, the nitrogen source is preferably an ammonia salt or urea, more preferably an ammonia salt.When the algae belonging to the class Polytrichum are those belonging to the genus Cyanidium, the nitrogen source is preferably an ammonia salt or nitrate, more preferably an ammonia salt.
[0048] As described above, algae belonging to the class Polytrichum can be grown at high density under a relatively wide range of culture conditions. Examples of pH conditions include pH 1.0 to 6.0, and pH 1.0 to 5.0 is preferred. When culturing outdoors, it is preferred to culture under highly acidic conditions to prevent the growth of other organisms, and examples of such conditions include pH 1.0 to 3.0. The temperature conditions can be, for example, 15 to 50° C., and preferably 30 to 50° C. When culturing outdoors, it is preferable to culture at high temperatures to prevent the proliferation of other organisms, and such conditions can be 35 to 50° C. The light intensity is 5 to 2000 μmol / m 2 Examples of the range are 5 to 1500 μmol / m 2 When culturing outdoors, the cells may be cultured under sunlight. When culturing indoors, the cells may be cultured under continuous light or with a light / dark cycle (e.g., 10L:14D).
[0049] <Drugs> The drug contained in the acid-resistant cells is not particularly limited and may be any drug. Examples of the drug include, but are not limited to, low molecular weight compounds, peptides, proteins, nucleic acids, lipids, sugars, vitamins, hormones, synthetic polymer compounds, etc. Among these, the drug is preferably at least one drug selected from the group consisting of low molecular weight compounds, peptides, proteins, and nucleic acids.
[0050] As the low molecular weight compound, low molecular weight compounds known as active ingredients of pharmaceuticals can be used without any particular limitation. The low molecular weight compound may be a contrast agent, a fluorescent dye, etc. used in diagnostic drugs. Examples of the low molecular weight compound include, but are not limited to, immunostimulants, anticancer drugs, signal transmission inhibitors, metabolic antagonists, analgesics, anti-inflammatory drugs, antibiotics, antiallergic drugs, drugs for treating central nervous system diseases, drugs for treating circulatory organ diseases, drugs for treating respiratory organ diseases, drugs for treating digestive organ diseases, drugs for treating urogenital organ diseases, contrast agents, fluorescent dyes, etc. The low molecular weight compound is not limited to the active ingredients of pharmaceuticals, and may be a component in food (e.g., nutritional components such as amino acids and vitamins, etc.) and a food additive (flavoring, etc.).
[0051] Examples of nucleic acids include nucleic acid molecules used as nucleic acid medicines (such as siRNA, miRNA, antisense RNA, aptamers, decoys, and CpG oligonucleic acids).
[0052] Synthetic polymer compounds include granular or spherical polymer compounds that are industrially produced, such as polyolefins, polyesters, and polyamides, some of which are expected to have immunostimulatory effects. The drug may be a microcapsule containing a low molecular weight compound, or may be a sustained release microcapsule, or a microcapsule that releases the drug depending on the environment, such as temperature, pH, or pressure.
[0053] As the peptide or protein (hereinafter collectively referred to as "drug peptide"), any peptide or protein known as an active ingredient of a pharmaceutical can be used without any particular limitation. Examples of drug peptides include, but are not limited to, antigens, cytokines, growth factors, hormones, enzymes, antibodies, antibody fragments, ligands, blood component proteins, etc. Among them, the drug peptide is preferably one having immunogenicity. The drug peptide "has immunogenicity" means that the drug peptide induces immunity against the drug peptide in a living body administered with the drug peptide. The immunity induced by the drug peptide may be cellular immunity, humoral immunity, or both.
[0054] It is more preferable that the drug peptide contributes to intestinal immunity. "Intestinal immunity" refers to a biological defense system that prevents foreign substances from entering the body through the intestine. The intestinal immune system is composed of lymphatic tissues such as Peyer's patches, immune cells in the lamina propria of the mucosa, intestinal epithelial cells, and lymphocytes present therebetween. The drug peptide that contributes to intestinal immunity can act on any one or more of these intestinal immune systems to strengthen the intestinal immune system.
[0055] Examples of drug peptides that contribute to intestinal immunity include immunogenic peptides or immunogenic proteins of pathogenic microorganisms or pathogenic viruses (hereinafter collectively referred to as "pathogens"). The immunogenic drug peptides can be appropriately selected depending on the infectious disease suffered by the subject to which the drug delivery composition of the present embodiment is applied. The immunogenic peptides or immunogenic proteins are also referred to as antigenic peptides or antigenic proteins.
[0056] For example, when the drug delivery composition of the present embodiment is applied to humans, the drug peptide can be an immunogenic peptide or immunogenic protein of a human pathogen. Examples of human pathogens include, but are not limited to, rabies virus, rotavirus, influenza virus, AIDS virus, poliovirus, hepatitis A virus, hepatitis B virus, human papillomavirus, Vibrio cholerae, Salmonella enterica, Mycobacterium tuberculosis, Streptococcus pneumoniae, Bacillus anthracis, and Salmonella typhi. For example, when the drug delivery composition of the present embodiment is applied to livestock, the drug peptide may be an immunogenic peptide or immunogenic protein of a livestock pathogen, such as, but not limited to, rabies virus, bovine rotavirus, bovine coronavirus, Akabane virus, bovine adenovirus, bovine parainfluenza virus, bovine Salmonella, Mycobacterium tuberculosis, porcine circovirus, porcine influenza virus, porcine parvovirus, hog cholera virus, and porcine streptococcus. Immunogenic peptides or immunogenic proteins can be designed using, for example, the full-length protein or a partial peptide thereof of a protein constituting the envelope or capsid of a pathogenic virus, or the full-length protein or a partial peptide thereof of a cell membrane protein of a pathogenic bacterium. For example, when the pathogen is the rabies virus, an example of the immunogenic protein is the full-length glycoprotein (base sequence: SEQ ID NO: 1, amino acid sequence: SEQ ID NO: 2) or a partial peptide thereof.
[0057] (Localization of drugs in sac-like membrane structures) In the acid-resistant cells, the drug is preferably localized in a sac-like membrane structure possessed by the acid-resistant cells. In this specification, the term "sac-like membrane structure" refers to a structure partitioned into a sac-like shape by a biomembrane or a biomembrane-mimicking structure, and specific examples include a cell membrane, a cell organelle, and an exogenous liposome. Examples of the cell organelle include, but are not limited to, mitochondria, chloroplasts, endoplasmic reticulum, vacuoles, cell nuclei, peroxisomes, and Golgi bodies. The term "exogenous liposome" refers to a liposome introduced into a cell from the outside. By localizing the drug in the sac-like membrane structure of the acid-resistant cells, the drug can be inhibited from being decomposed by decomposition enzymes in the cytoplasm, and therefore the drug is protected from being decomposed by intracellular enzymes until the acid-resistant cells are delivered to a specific site in the body (e.g., the intestine) and rupture.
[0058] The method of localizing a drug in a saccular membrane structure is not particularly limited, and examples thereof include a method using a signal peptide (hereinafter referred to as a "translocation signal") that instructs the transfer to an arbitrary saccular structure or a protein (hereinafter referred to as a "translocation protein") that transfers to the saccular structure. For example, a drug can be localized in the saccular structure by binding a transport signal or transport protein that targets an arbitrary saccular structure to the drug and introducing the resulting mixture into an acid-resistant cell. For example, when a drug is localized in any of mitochondria, vacuoles, peroxisomes, endoplasmic reticulum, cell membrane, Golgi apparatus, and cell nucleus, a transport signal or transport protein for mitochondria, vacuoles, peroxisomes, endoplasmic reticulum, cell membrane, Golgi apparatus, or cell nucleus can be bound to the drug. These transport signals and transport proteins can be selected from various known sources depending on the type of acid-resistant cells. Alternatively, the saccular membrane structure in which a drug is to be localized may be isolated from acid-resistant cells by a cell fractionation method such as density gradient centrifugation, and the proteins in the saccular membrane structure may be analyzed to obtain a transport signal or transport protein for the saccular membrane structure.
[0059] For example, when Cyanidioschyzon melorae is used as the acid-resistant cell, the following can be used as the migration signal or migration protein: As a transport protein for chloroplasts, a protein consisting of 130 residues (nucleotide sequence: SEQ ID NO: 5, amino acid sequence: SEQ ID NO: 6) on the N-terminus of the chloroplast preprotein translocase SecA subunit (CMQ393C; nucleotide sequence: SEQ ID NO: 3, amino acid sequence: SEQ ID NO: 4) can be used (Sumiya et al. 2016, Proc Natl Acad Sci US A. 113(47):E7629-E7638; PMID: 27837024). A peptide consisting of the N-terminal 78 residues (nucleotide sequence: SEQ ID NO: 9, amino acid sequence: SEQ ID NO: 10) of EF-TU (CMS502C) (nucleotide sequence: SEQ ID NO: 7, amino acid sequence: SEQ ID NO: 8) can be used as a transport signal for the mitochondrial matrix (Imoto et al. 2013, BMJ. 300(6735):1316-8; PMID: 2369666). Examples of proteins that can be used for transport to the vacuole include prenylated Rab acceptor PRA1 (CMJ260C) (nucleotide sequence: SEQ ID NO: 7, amino acid sequence: SEQ ID NO: 8), ABC transporter (CMS401C) (nucleotide sequence: SEQ ID NO: 13, amino acid sequence: SEQ ID NO: 14), and o-methyltransferase (CMT369C) (nucleotide sequence: SEQ ID NO: 15, amino acid sequence: SEQ ID NO: 16) (Yagisawa et al. 2009, Plant J. 60(5):882-93; PMID: 19709388). Catalase (CMI050C) (nucleotide sequence: SEQ ID NO: 17, amino acid sequence: SEQ ID NO: 18) can be used as a transport protein for peroxisomes (Moriyama et al. 2014, Planta. 240(3):585-98; PMID: 25009310). Examples of proteins that can be used for transporting to the endoplasmic reticulum include ACC1 (CMM188C) (nucleotide sequence: SEQ ID NO: 19, amino acid sequence: SEQ ID NO: 20), PAP (CMT239C) (nucleotide sequence: SEQ ID NO: 21, amino acid sequence: SEQ ID NO: 22), and ALA1 (CMR396C) (nucleotide sequence: SEQ ID NO: 23, amino acid sequence: SEQ ID NO: 24) (Mori et al. 2016, Front Plant Sci. 7:958; PMID: 27446184). ALA1(CMR396C) and the like can be used as a transport protein for the cell membrane (Mori et al. 2016, Front Plant Sci. 7:958; PMID: 27446184). Since ALA1(CMR396C) is also a transport protein for the endoplasmic reticulum, it is possible to localize drugs to both the cell membrane and the endoplasmic reticulum by using ALA1(CMR396C). As a transport protein for the Golgi apparatus, Got1 (CMI302C) (nucleotide sequence: SEQ ID NO: 25, amino acid sequence: SEQ ID NO: 286) or the like can be used (Yagisawa et al. 2013, Protoplasma. 250(4):943-8; PMID: 23197134). Examples of proteins that can be used to transport to the cell nucleus include Topoisomerase I type IB (CMM263C) (nucleotide sequence: SEQ ID NO: 27, amino acid sequence: SEQ ID NO: 28) (Moriyama et al. 2014, Genome Biol Evol. 6(1):228-37; PMID: 24407855).
[0060] When the drug is a drug peptide, the drug peptide may be encapsulated in the acid-resistant cells as a fusion protein with a transport signal or transport protein. By making the drug peptide into a fusion protein with a transport signal or transport protein, the drug peptide can be localized in the sac-like membrane structure targeted by the transport signal or transport protein. For example, a gene encoding a fusion protein of a drug peptide and a transport signal or transport protein (hereinafter also referred to as a "fusion protein gene") is introduced into an acid-resistant cell, and the fusion protein is expressed in the acid-resistant cell, whereby the fusion protein is transported to a sac-like membrane structure targeted by the transport signal or transport protein. As a result, the drug peptide contained in the fusion protein is localized in the sac-like membrane structure. Therefore, in a preferred embodiment, the acid-resistant cell is a cell into which a fusion protein gene encoding a fusion protein comprising a transport signal or transport protein and a drug peptide has been introduced in an expressible state, and is a cell having the fusion protein gene. In a preferred embodiment, the acid-resistant cell is a cell expressing the fusion protein gene. The fusion protein gene may contain, in addition to the coding sequence of the drug peptide and the coding sequence of the transport signal or transport protein, a sequence encoding a peptide that improves recognition by intestinal cells, etc. An example of a peptide that improves recognition by intestinal cells is Co1 peptide (SEQ ID NO: 43).
[0061] The fusion protein gene of the drug peptide and the transport signal or transport protein is preferably operably linked to a promoter capable of functioning in acid-resistant cells. The promoter is not particularly limited as long as it is capable of functioning in acid-resistant cells, but from the viewpoint of maintaining the amount of drug in the cells, it is preferable that the promoter is a housekeeping gene with a high expression level. For example, when the acid-resistant cells are Cyanidioschyzon melorae, the promoter can be, for example, an APCC (CMO250C) promoter (e.g., -600 to -1; "-1" indicates the nucleotide immediately before the start codon), a CPCC (CMP166C) promoter, a Catalase (CMI050C) promoter, etc. The promoter sequence of APCC from Cyanidioschyzon merolae is shown in SEQ ID NO: 29, the promoter sequence of CPCC (CMP166C) from Cyanidioschyzon merolae is shown in SEQ ID NO: 30, and the promoter sequence of Catalase (CMI050C) from Cyanidioschyzon merolae is shown in SEQ ID NO: 31. These promoters from Cyanidioschyzon merolae can also be used in other algae belonging to the class Polytrichum.
[0062] The gene encoding the fusion protein is introduced into the acid-tolerant cells in an expressible state, for example, in the form of an expression vector. In addition to the fusion protein and a promoter, the expression vector may contain a control sequence such as an enhancer, a polyA addition signal, a terminator, and a 3'UTR, and a marker gene such as a drug resistance gene. An example of the terminator and 3'UTR is the 3'UTR of β-tubulin. The type of vector is not particularly limited, and a commonly used expression vector can be appropriately selected and used depending on the type of acid-resistant cell. The vector may be linear or circular, and may be a non-viral vector such as a plasmid, a viral vector (e.g., a retroviral vector such as a lentiviral vector), or a transposon-based vector.
[0063] When the acid-tolerant cells are Cyanidioschyzon merolae, the URA5.3 gene (CMK046C) may be used as a selection marker. Cyanidioschyzon merolae has a uracil auxotrophic mutant, Cyanidioschyzon merolae M4 (Minoda et al., Plant Cell Physiol. 2004 Jun;45(6):667-71.). Cyanidioschyzon merolae M4 has a mutation in the URA5.3 gene and cannot synthesize uracil. Therefore, Cyanidioschyzon merolae M4 cannot grow in a medium that does not contain uracil. Therefore, by using Cyanidioschyzon merolae M4 as a parent strain and the wild-type URA5.3 gene as a selection marker, transformants into which the fusion gene has been introduced can be selected. More specifically, the fusion protein gene operably linked to a promoter is linked to the URA5.3 gene set of a Cyanidioschyzon merolae wild strain (e.g., 10D strain), and the resulting product is introduced into the Cyanidioschyzon merolae M4 strain. Then, the cells into which the fusion protein gene has been introduced can be obtained by culturing the cells in a medium that does not contain uracil.
[0064] The method for introducing an arbitrary fusion protein gene into acid-resistant cells is not particularly limited, and any known method can be used. Examples of gene introduction methods include the polyethylene glycol method, the lipofection method, the microinjection method, the DEAE-dextran method, the gene gun method, the electroporation method, and the calcium phosphate method.
[0065] The fusion protein gene may be present as a plasmid or the like in the acid-tolerant cell, or may be inserted into any of the nuclear genome, the chloroplast genome, and the mitochondrial genome. When the fusion protein gene is inserted into the genome, it may be inserted into a specific position of the genome or may be inserted randomly into the genome. A method for inserting a fusion protein gene into a specific position in the genome can be performed by homologous recombination. For example, the entire genome sequence of C. melorae has been completed (Matsuzaki M et al., Nature. 2004 Apr 8;428(6983):653-7.), so it is possible to insert a fusion protein gene into a desired position on the genome. The insertion position of the fusion protein gene in C. melorae is not particularly limited, but an example of the insertion position is the region between CMD184C and CMD185C.
[0066] In the fusion protein gene, the order in which the drug peptide and the transport signal or transport protein are arranged is appropriately selected depending on the type of the transport signal or transport protein. In general, the coding sequence of the transport signal or transport protein is arranged on the 5' side of the coding sequence of the drug peptide.
[0067] When a gene encoding a drug peptide (hereinafter referred to as "drug peptide gene") is inserted into the chloroplast genome or mitochondrial genome, the drug peptide does not necessarily need to be a fusion protein with a transport signal or transport protein. For example, the drug peptide gene can be operably linked to a promoter capable of functioning in chloroplasts, inserted into the chloroplast genome in an expressible state, and expressed in the chloroplast, thereby localizing the drug peptide in the chloroplast. Similarly, the drug peptide gene can be operably linked to a promoter capable of functioning in mitochondria, inserted into the mitochondrial genome in an expressible state, and expressed in the mitochondria, thereby localizing the drug peptide in the mitochondria.
[0068] In the drug delivery composition of this embodiment, the drug is preferably localized in an organelle, more preferably in a chloroplast. The drug is preferably a drug peptide, and is preferably localized in an organelle targeted by the transport signal or transport protein in the form of a fusion protein with the transport signal or transport protein. The transport signal or transport protein is more preferably a chloroplast transport signal or chloroplast transport protein.
[0069] <Optional ingredients> The drug delivery composition of the present embodiment may contain other components in addition to the acid-resistant cells. Examples of other components include, but are not limited to, pharma- ceutically acceptable carriers. The term "pharma-ceutically acceptable carrier" refers to a carrier that does not inhibit the function of the drug contained in the acid-resistant cells and does not show substantial toxicity to the administration subject. The term "not substantially toxic" refers to the fact that the component does not show toxicity to the administration subject at the dose normally used. The pharma-ceutically acceptable carrier includes, but is not limited to, excipients, binders, disintegrants, lubricants, emulsifiers, stabilizers, diluents, oily bases, thickeners, antioxidants, reducing agents, oxidizing agents, chelating agents, solvents, and the like. The pharma-ceutically acceptable carrier may be used alone or in combination of two or more types. It is preferable that the pharma-ceutically acceptable carrier does not damage the acid-resistant cells.
[0070] The drug delivery composition of the present embodiment can be mixed with other ingredients as appropriate and made into the form of granules, tablets, jellies, liquids, capsules, etc. according to a standard method. Among these drug forms, drug forms that do not damage acid-resistant cells are preferred, for example, jellies, liquids, capsules, etc. are preferred. For example, as shown in the examples described below, the drug delivery composition may be made into the form of a solidified alginic acid containing acid-resistant cells. In addition to alginic acid, a thickening or gelling agent such as gelatin, agar, carrageenan, roasted bean gum, guar gum, xanthan gum, pectin, gellan gum, tamarind seed gum, or gum arabic may be used to solidify the suspension containing acid-resistant cells, and the suspension may be used as the drug delivery composition of the present embodiment. The medium used for suspending the acid-resistant cells is not particularly limited, but is preferably one that does not cause cell rupture of the acid-resistant cells, and is preferably an isotonic solution of about pH 1 to 6. Examples of the isotonic solution include a medium used for culturing acid-resistant cells, an isotonic glucose solution adjusted to about pH 1 to 6, an isotonic sucrose solution, and various buffer solutions (phosphate buffered saline, HEPES buffer, citrate buffer, Tris buffer, etc.). In one embodiment, the drug delivery composition is a solidified body of acid-resistant cells using a thickening agent or a gelling agent. By solidifying the acid-resistant cells using a thickening agent and / or a gelling agent, it is possible to prevent the acid-resistant cells from drying. The term "solidified body of acid-resistant cells using a thickening agent or a gelling agent" refers to a suspension of acid-resistant cells gelled and solidified using a thickening agent or a gelling agent. In other words, the term "solidified body of acid-resistant cells using a thickening agent or a gelling agent" is a gel composition containing acid-resistant cells and at least one selected from the group consisting of a thickening agent and a gelling agent.
[0071] The administration route of the drug delivery composition of this embodiment is not particularly limited, and may be oral administration or parenteral administration, but is preferably oral administration. In the drug delivery composition of this embodiment, the drug is encapsulated in acid-resistant cells, so that the decomposition of the drug by gastric acid can be suppressed. Therefore, the drug delivery composition of this embodiment is suitable for oral administration. The drug delivery target of the drug delivery composition of this embodiment is preferably the intestine (intestinal tract), more preferably the small intestine. When the drug delivery composition of this embodiment is orally administered, the drug is protected within the cells of the acid-resistant cells and passes through the stomach. Next, when the composition reaches the intestine, the acid-resistant cells undergo cell rupture due to the neutral to weakly alkaline pH conditions (pH 7 or higher) in the intestinal tract, and the drug is released into the intestinal tract. The drug released into the intestinal tract acts in the intestinal tract and contributes to strengthening intestinal immunity, etc. Furthermore, strengthening intestinal immunity is expected to activate other mucosal immunity and systemic immunity as well.
[0072] As described above, according to the drug delivery composition of the present embodiment, since the drug is encapsulated in the acid-resistant cells, the decomposition of the drug in the stomach is suppressed, and the drug can be delivered to the intestine. Furthermore, since the drug is localized in the sac-like membrane structure in the acid-resistant cells, the drug is protected from decomposition by decomposition enzymes in the cytoplasm. Furthermore, by using acid-resistant cells into which a drug peptide gene or a fusion protein gene containing a drug peptide coding sequence has been introduced, it is possible to easily grow the drug-containing acid-resistant cells. In particular, algae belonging to the class Polytrichum can grow under highly acidic conditions in which other organisms cannot survive, and therefore can be mass-cultured outdoors. This is expected to reduce the production cost.
[0073] [feed] In one embodiment, the present invention provides a feed comprising the drug delivery composition of the above embodiment.
[0074] The type of animals to which the feed of the present embodiment is given is not particularly limited, and examples thereof include livestock (cattle, pigs, chickens, horses, sheep, goats, etc.), pets (dogs, cats, hamsters, rabbits, parakeets, tropical fish, reptiles, amphibians, insects, etc.), aquatic animals (fish, shellfish, etc.), and laboratory animals (mice, rats, guinea pigs, etc.), but are not limited to these.
[0075] The feed of the present embodiment may contain other ingredients in addition to the drug delivery composition of the above embodiment. Examples of other ingredients include commonly used feed (including livestock feed, aquatic feed, and pet food). For example, the drug delivery composition of the above embodiment may be added to existing feed as a feed additive. The feed to which the drug delivery composition of the above embodiment is added is not particularly limited and may be appropriately selected depending on the target animal. By adding the drug delivery composition of the above embodiment to normal feed and feeding it to an animal, the animal can ingest the drug through normal feeding behavior.
[0076] The drug delivery composition used in the feed of the present embodiment may be in any form, but in order to prevent drug leakage from the acid-resistant cells, it is preferable that the acid-resistant cells are not damaged. For example, the above-mentioned jelly, capsule, and form solidified with a gelling agent and / or thickener can be mentioned. When the drug delivery composition is added to the feed as a feed additive, for example, a solidified body of the drug delivery composition using a thickener and / or gelling agent may be prepared to an appropriate size, and added to the feed and mixed. Alternatively, the drug delivery composition may be added to the feed and mixed, and then the mixture may be solidified using a gelling agent and / or thickener. The solidified body can be prepared to an appropriate size according to the size of the animal. By solidifying the body using a thickener and / or gelling agent, it is possible to prevent the acid-resistant cells from drying out.
[0077] The content of the drug delivery composition of the above embodiment in the feed of the present embodiment is not particularly limited, and may be appropriately set according to the type of feed. For example, the content of the drug delivery composition in the feed is 0.01-80% by mass, preferably 0.1-70% by mass, more preferably 0.1-60% by mass, and particularly preferably 0.1-50% by mass. The content of the acid-resistant cells in the feed is, for example, 0.1-100 mg (wet weight) / g, 0.5-80 mg (wet weight) / g, 1-60 mg (wet weight) / g, etc.
[0078] According to the feed of this embodiment, since it contains the drug delivery composition of the above embodiment, any drug can be ingested by animals as feed. As described above, the drug delivery composition can protect any drug from degradation in the stomach and deliver it to the intestine. Therefore, by using a drug that acts in the intestine in the drug delivery composition, the drug can be efficiently acted on the intestine of the animal. In addition, when the drug is a drug peptide having immunogenicity, the intestinal immunity can be efficiently activated in the animal that ingested the drug delivery composition. Furthermore, it is expected that the activation of the intestinal immunity will also activate other mucosal immunity and systemic immunity.
[0079] In another aspect, the present invention provides a method of feeding an animal comprising feeding the animal a feed comprising the drug delivery composition of the above embodiments. In yet another aspect, the present invention provides a method for conferring intestinal immunity to an animal, comprising feeding the animal a feed containing the drug delivery composition of the above embodiment.
[0080] [Drugs] In one embodiment, the present invention provides a pharmaceutical product comprising the drug delivery composition of the above embodiments.
[0081] The pharmaceutical of the present embodiment may be a pharmaceutical for human use or a pharmaceutical for animals. In the case of a pharmaceutical for animals, the type of animal to which the pharmaceutical is applied is not particularly limited. For example, livestock (cattle, pigs, chickens, horses, sheep, goats, etc.), pets (dogs, cats, hamsters, rabbits, parakeets, tropical fish, reptiles, amphibians, insects, etc.), aquatic animals (fish, shellfish, etc.), and laboratory animals (mice, rats, guinea pigs, etc.) can be mentioned, but are not limited thereto.
[0082] The pharmaceutical of this embodiment may contain other components in addition to the drug delivery composition of the above embodiment. Examples of other components include, but are not limited to, pharma- ceutically acceptable carriers. The term "pharma-ceutically acceptable carrier" refers to a carrier that does not inhibit the function of a drug and does not show substantial toxicity to the subject of administration. In addition, "not substantially toxic" means that the component does not show toxicity to the subject of administration at a dose that is normally used. Examples of pharma-ceutically acceptable carriers include, but are not limited to, excipients, binders, disintegrants, lubricants, emulsifiers, stabilizers, diluents, oily bases, thickeners, antioxidants, reducing agents, oxidizing agents, chelating agents, solvents, and the like. One type of pharma-ceutically acceptable carrier may be used alone, or two or more types may be used in combination. The other components may be components other than those described above, and for example, pharmaceutical additives commonly used in pharmaceuticals may be used without any particular restrictions. The other components may also be active components other than the drug contained in the drug delivery composition. The active substance is not particularly limited, but examples thereof include intestinal regulators, anti-inflammatory agents, antibiotics, antibacterial substances, herbal medicines, digestive stimulants, antipyretics, and analgesics.
[0083] The dosage form of the pharmaceutical of the present embodiment is not particularly limited, but in order to prevent drug leakage from the acid-resistant cells, it is preferable that the form does not damage the acid-resistant cells. For example, tablets, granules, jellies, capsules, liquids, syrups, etc. may be mentioned. For example, the pharmaceutical of the present embodiment may contain a solidified body of acid-resistant cells using a thickening agent and / or a gelling agent.
[0084] The content of the drug delivery composition of the above embodiment in the pharmaceutical product of the present embodiment is not particularly limited, and the content may be appropriately set according to the type of drug contained in the drug delivery composition. For example, the content of the drug delivery composition in the pharmaceutical product is 0.01 to 80 mass%, preferably 0.1 to 70 mass%, more preferably 0.1 to 60 mass%, and particularly preferably 0.1 to 50 mass%. The content of the acid-resistant cells in the pharmaceutical product is, for example, 0.1 to 100 mg (wet weight) / g, 0.5 to 80 mg (wet weight) / g, 1 to 60 mg (wet weight) / g, etc.
[0085] The administration route of the pharmaceutical of this embodiment is not particularly limited, and may be oral administration or parenteral administration, but is preferably oral administration. In the pharmaceutical of this embodiment, the drug is encapsulated in acid-resistant cells, so that decomposition of the drug by gastric acid can be suppressed. The drug delivery target of the pharmaceutical agent of this embodiment is preferably the intestine (intestinal tract), more preferably the small intestine.
[0086] According to the pharmaceutical of this embodiment, since it contains the drug delivery composition of the above embodiment, any drug can be protected from degradation in the stomach and delivered to the intestine. Therefore, by using a drug that acts in the intestine in the drug delivery composition, the drug can be efficiently acted on the intestine. In addition, when the drug is a drug peptide having immunogenicity, the intestinal immunity can be efficiently activated in an animal that has ingested the drug delivery composition. Furthermore, it is expected that the activation of the intestinal immunity will also activate other mucosal immunity and systemic immunity. Therefore, the pharmaceutical of the present embodiment can be used for the prevention and treatment of human diseases and for health promotion. In particular, the pharmaceutical can be suitably used for drugs that are desired to be absorbed in the intestine rather than the stomach, drugs that are decomposed or insolubilized by gastric acid and thus prevented from being absorbed in the intestine, and pharmaceuticals for absorbing multiple drugs in the intestine at once.
[0087] In another aspect, the present invention provides a method of administering a drug, comprising orally administering to a subject a pharmaceutical agent comprising the drug delivery composition of the above embodiments. In another aspect, the present invention provides a method for conferring intestinal immunity to a subject, comprising orally administering to the subject a pharmaceutical agent comprising the drug delivery composition of the above embodiment.
[0088] [Food] In one embodiment, the present invention provides a food product comprising the drug delivery composition of the above embodiments.
[0089] The food of this embodiment may be a general food, a nutritional supplement, a functional food, a supplement, etc. The drug delivery composition may be added to the food as a food additive.
[0090] In the food of the present embodiment, the type of food is not particularly limited, but in order to prevent drug leakage from the acid-resistant cells, it is preferable that the acid-resistant cells are in a form that does not damage the cells, and it is preferable that the food is not a dry food. Examples of the food include, but are not limited to, beverages such as green juice, soft drinks, carbonated drinks, nutritional drinks, fruit drinks, vegetable drinks, lactic acid drinks, milk drinks, sports drinks, tea, coffee, etc.; various soups such as curry roux, stew roux, instant soup, etc.; cold desserts such as ice cream, ice sherbet, shaved ice, etc.; confectioneries such as candy, jelly, jam, cream, etc.; fishery and livestock processed foods such as kamaboko, hanpen, ham, sausage, etc.; dairy products such as processed milk, fermented milk, butter, cheese, yogurt, etc.; seasonings such as sauce, dressing, miso, soy sauce, sauce, etc.; and other processed foods such as various retort foods.
[0091] In the food of this embodiment, the content of the drug delivery composition is not particularly limited, and may be appropriately set according to the type of food. For example, taking into consideration the flavor of the food, the content of the drug delivery composition in the food is, for example, 0.01 to 80 mass%, preferably 0.1 to 70 mass%, more preferably 0.1 to 60 mass%, and particularly preferably 0.1 to 50 mass%. The content of the acid-resistant cells in the food is, for example, 0.1 to 100 mg (wet weight) / g, 0.5 to 80 mg (wet weight) / g, 1 to 60 mg (wet weight) / g, etc.
[0092] Furthermore, when the food is a functional food, a nutritional supplement, or a supplement, it may be in the form of a general food as described above, or in the form of a granule, a tablet, a jelly, a drink, etc. For example, the food of this embodiment may contain a solidified body of acid-resistant cells with a thickening agent and / or a gelling agent.
[0093] According to the food of this embodiment, since it contains the drug delivery composition of the above embodiment, any drug can be ingested as food. As described above, the drug delivery composition can protect any drug from being decomposed in the stomach and deliver it to the intestine. The food of this embodiment is useful when one or more specific nutritional components are to be absorbed in the intestine without being affected by gastric acid.
[0094] [Drug Carrier] In one embodiment, the present invention provides a drug carrier comprising acid-tolerant cells. The acid-resistant cells contained in the drug carrier of this embodiment are the same as the acid-resistant cells described in "<Acid-resistant cells>" of the above-mentioned "[Drug delivery composition]", and preferred examples are also similar. The acid-resistant cells are resistant to acid, and are not damaged even in an acidic environment such as the stomach. Therefore, by encapsulating a drug in the cells, they can be used as an acid-resistant drug carrier. Methods for encapsulating a drug in the cells include the same methods as those described in the above-mentioned "[Drug delivery composition]". The drug carrier of this embodiment is preferably composed of acid-resistant cells. The drug carrier of the present embodiment can be suitably used for delivering a drug to the intestine, and can be suitably applied to pharmaceuticals that are orally administered, or feed or food that is orally ingested.
[0095] [Drug Capsules] In one embodiment, the present invention provides a drug capsule in which a drug is encapsulated in the drug carrier of the above embodiment. The acid-resistant cells contain drugs in the cells, and as shown in the examples below, the release of drugs hardly occurs in an acidic environment such as the stomach. Therefore, the drug carrier containing the acid-resistant cells can be used as an acid-resistant drug capsule by containing drugs in the cells of the acid-resistant cells. The drug capsule of this embodiment can be used as an oral drug capsule for the purpose of delivering drugs to the intestine.
[0096] [Acid-resistant cells] In one embodiment, the present invention provides an acid-tolerant cell that encapsulates a drug in the cell. In a preferred embodiment, the drug is localized in a sac-like membrane structure of the acid-tolerant cell. The acid-resistant cells of this embodiment are similar to the acid-resistant cells contained in the drug delivery composition of the above embodiment, and the preferred examples are also similar. Alternatively, the drug is localized outside the sac-like membrane structure of the acid-resistant cells. When the drug is localized outside the sac-like membrane structure, the drug is present in the cytoplasm of the acid-resistant cells.
[0097] The drug is not particularly limited, but is preferably at least one drug selected from the group consisting of low molecular weight compounds, peptides, proteins, and nucleic acids. For example, when the drug is protected from the effects of decomposition enzymes in the cytoplasm, the drug is preferably localized in the sac-like membrane structure. By localizing in the sac-like membrane structure, the drug is protected from the effects of decomposition enzymes in the cytoplasm. Therefore, the drug can be efficiently delivered to a predetermined site in the living body. For example, when the drug is a peptide, protein, or nucleic acid, it is susceptible to the effects of proteases or nucleases in the cytoplasm. Therefore, it is preferably localized in the sac-like membrane structure. On the other hand, when the drug is not susceptible to the effects of decomposition enzymes in the cytoplasm (for example, low molecular weight compounds), the drug may be localized outside the sac-like membrane structure.
[0098] In one embodiment, the present invention also provides an acid-tolerant cell comprising an exogenous substance. The acid-resistant cells of this embodiment are similar to the acid-resistant cells described in the above section "[Drug delivery composition]" under "<Acid-resistant cells>", and preferred examples are also similar. The exogenous substance is not particularly limited, and includes, but is not limited to, drugs, poisons, dyes, fragrances, and compounds whose effects on living organisms are unknown. The method of introducing the exogenous substance into acid-resistant cells is not particularly limited, and examples thereof include a method of binding to a cell-permeable substance (such as a cell-permeable peptide) and a method of encapsulating the exogenous substance in a cell-permeable micelle. In addition, when the exogenous substance is a drug, the same method as described in the above "Drug delivery composition" can be used. The acid-resistant cells of the present embodiment can be used, for example, to deliver exogenous substances. More specifically, the acid-resistant cells of the present embodiment can be applied to an oral composition for delivering exogenous substances to the intestine.
[0099] In another aspect, the present invention provides a feed containing the acid-tolerant cells. In another aspect, the present invention provides a pharmaceutical product containing the acid-resistant cells. In another aspect, the present invention provides a food product containing the acid-tolerant cells. In another aspect, the present invention provides a method for administering the exogenous substance, comprising orally administering the acid-resistant cells to a subject. In another aspect, the present invention provides a method for raising an animal, comprising feeding the acid-resistant cells to the animal. In another aspect, the present invention provides a method for conferring intestinal immunity, which comprises orally administering the acid-resistant cells.
[0100] [Method of producing acid-resistant cells] In one embodiment, the present invention provides a method for producing acid-tolerant cells encapsulating a drug, comprising the step of introducing into acid-tolerant cells a gene encoding a fusion protein comprising a peptide or protein as a drug and a peptide or protein that localizes to a cell membrane or an organelle. The production method of this embodiment can be carried out as described above in "[Drug delivery composition] <Acid-resistant cells> (localization of drug in pouch-like membrane structure)". EXAMPLES
[0101] The present invention will be described below with reference to examples, but the present invention is not limited to the following examples.
[0102] [Example 1] (Generation of GAPDH-GP-sfGFP expressing strains) To insert the GAPDH-GP-sfGFP DNA fragment downstream of CMD184C (gene number) on the chromosome of Cyanidioschyzon merolae 10D, the plasmid pD184-HSp-GAPDH-GP-sfGFP was first prepared as follows. This plasmid was designed so that the following sequences were arranged in order in the multicloning site of pQE80 plasmid (for maintenance and replication in E. coli; manufactured by QIAGEN): The sequence consists of the latter half of the CMD184C gene (773-2773bp of the gene open reading frame (ORF) and 25bp downstream including the stop codon), a heat shock (HS) promoter (200bp upstream sequence adjacent to the start codon of the HSP20 / CMJ101C gene; Sumiya et al. 2014, PLoS One. 22;9(10):e111261; PMID:25337786), GAPDH (1bp-1209bp of the open reading frame of the CMJ042C gene; GAPDH is described in Moriyama et al. 2014, Planta. 240(3):585-98; PMID:25009310), and the rabies virus glycoprotein gene GP (1-1572bp of the ORF, UniProtKB accession no. 14411). The HS promoter is required to induce the expression of GAPDH-GP-sfGFP by heating the medium. The URA selection marker is required to select the GAPDH-GP-sfGFP strain. The latter half and downstream sequence of CMD184C and downstream of the CMD185C gene are required to insert a DNA fragment downstream of CMD184C by homologous recombination.
[0103] First, in order to construct the plasmid pD184-HSp-GAPDH-GP-sfGFP, the following DNA fragments (1), (2), (3), (4), and (5) were prepared. (1) Plasmid pD184-APCCp-EGFP-URACm-Cm Using pQE80 (sequence number 32), the latter half of CMD184C (sequence number 33), APCC promoter (sequence number 34), EGFP (sequence number 35), β-tubulin terminator (sequence number 36), URA selection marker (sequence number 37), and DNA sequence downstream of the CMD185C gene (sequence number 38); Fujiwara et al. 2013, PLoS One. 8(9): e73608; PMID:24039997) as a template, the DNA sequence of the portion excluding the APCC promoter and EGFP was amplified by PCR using the primer set [#1d184(+25)R / #2bT3'(+1)F]. The nucleotide sequence of the DNA fragment of (1) is shown in Sequence Number 31. (2) The DNA sequence of the HS promoter (SEQ ID NO: 39) was amplified by PCR using the genomic DNA of C. merolae 10D as a template and the primer set [#3HS(-200)Fd184 / #4HS(-1)R]. (3) The GAPDH gene open reading frame (sequence number 40) was amplified by PCR using the genomic DNA of C. merolae 10D as a template and the primer set [#5J042(1)Fhs / #6J042(1209)R-link3]. (4) The DNA sequence of GP was chemically synthesized to match the codon usage frequency of C. merolae (sequence number 41), and this was used as a template for PCR amplification using the primer set [#7GP(1)F-linker3 / #8GP(1572)R-linker2]. (5) sfGFP (SEQ ID NO:42) was amplified by PCR using pAPCC-promoter-sfGFP-pmE2F-URA (Miyagishima et al 2014, Nat Commun. 5: 3807; PMID:24806410) as template and the primer set [#9sfGFP(1)F-linker2 / #10sfGFP(714)Rbt].
[0104] The above DNA fragments (1), (2), (3), (4), and (5) were mixed and fused using the In-Fusion® HD Cloning Kit (product code: 639648, TAKARA) to obtain pD184-APCCp-EGFP-URA Cm-Gs The HS promoter, GAPDH, GP, and sfGFP were inserted to replace the APCC promoter and EGFP portion of pD184. After the InFusion reaction, the plasmid was amplified by introducing it into E. coli competent cells to obtain pD184-HSp-GAPDH-GP-sfGFP. Next, using this as a template and the primer set [#11D184(1200)F / #12D184(+1400)R], a DNA fragment in which the latter half of the CMD184 gene (1200bp-2773bp of the gene ORF and 25bp downstream including the stop codon), the HS promoter, GAPDH, GP, sfGFP, β-tubulin terminator, URA selection marker, and the downstream of the CMD184C gene (the base sequence from 28bp downstream of the stop codon to 1440bp) were linked was amplified by PCR. This DNA fragment was introduced into a uracil-requiring C. merolae strain M4 (Minoda et al. 2004, Plant Cell Physiol.45(6):667-71.; PMID:15215501) by the PEG method (Ohnuma et al. 2008, Plant Cell Physiol.49(1):117-20; PMID:18003671), and selected on uracil-free MA2 solid medium to obtain a GAPDH-GP-sfGFP expressing strain.
[0105] (Assessment of proteasomal degradation of GAPDH-GP-sfGFP protein) The GAPDH-GP-sfGFP-expressing strain of C. merolae prepared as described above (hereinafter referred to as the "GAPDH-GP-sfGFP-expressing strain") was subcultured in 60 mL of MA2 medium in an Erlenmeyer flask at a cell density of OD750 = 0.2 and incubated under light irradiation (50 μmol m -2 s -1) and cultured at 40°C for 2 days with a gyratory rotation (before expression). Next, 20 mL of this culture medium was transferred to two Erlenmeyer flasks. To induce GAPDH-GP-sfGFP gene expression by heat stimulation, the two Erlenmeyer flasks were transferred to a 50°C incubator and cultured with a gyratory rotation for 1 hour under light irradiation. Just before transferring to 50°C, one of the two Erlenmeyer flasks was added with the proteasome inhibitor MG-132 to a final concentration of 100 μM to inhibit protein degradation by the proteasome (MG-132(+)) (Nishida et al 2005; Mol Biol Cell. 16(5):2493-502; PMID:15772156). The other Erlenmeyer flask was added with 40 μL of DMSO, the solvent for MG-132, as a control (MG-132(-)). The expression of GAPDH-GP-sfGFP protein was confirmed by immunoblotting, and the effect of proteasome inhibition was verified by comparing the band patterns. Anti-GFP antibody (clone JL-8, product code: 632381, Takara) was used to detect GAPDH-GP-sfGFP protein.
[0106] The results of immunoblotting are shown in Figure 1. The band of GAPDH-GP-sfGFP protein was weaker in MG-132(-) compared to MG-132(+). This result indicated that the GAPDH-GP-sfGFP protein was partially degraded by proteasome after expression.
[0107] (Analysis of intracellular localization of GAPDH-GP-sfGFP protein) To analyze the intracellular localization of GAPDH-GP-sfGFP protein, the GAPDH-GP-sfGFP expressing strain was cultured under light irradiation at 50°C in the presence of MG-132 for 1 hour, and the fluorescence of GAPDH-GP-sfGFP protein was observed under a fluorescence microscope.
[0108] Fluorescence microscopy images of the GAPDH-GP-sfGFP expressing strain are shown in Figure 2. The fluorescent signal of sfGFP indicated that the GAPDH-GP-sfGFP protein was localized in the cytoplasm. The image in Figure 2(A) (PC) is a phase contrast microscopy image showing the outline of the cell, the image in Figure 2(B) (Chl) is an autofluorescence image of the chloroplasts, and the image in Figure 2(C) (sfGFP) is a fluorescent image of sfGFP.
[0109] [Example 2] (Creation of Chl-TP-3HA-GP-Co1 expressing strain) In order to insert a DNA fragment for expressing Chl-TP-3HA-GP-Co1 (see Figure 3) downstream of CMD184C (gene number) on the chromosome of C. merolae 10D, we first prepared the plasmid pD184-APCCp-Chl-TP-3HA-GP-Co1 as follows. This plasmid was designed so that the following sequences were arranged in order from the 5' end in the multiple cloning site of the pQE80 plasmid: The sequence is as follows, from the 5' end: the latter half of the CMD184C gene (773bp-2773bp of the gene ORF and 25bp downstream including the stop codon), the APCC promoter (600bp of the upstream sequence adjacent to the APCC / CMO250C gene start codon), the chloroplast targeting signal Chl-TP (1bp-390bp of the SECA / CMQ393C gene ORF; Sumiya et al. 2016, Proc Natl Acad Sci U S A. 113(47):E7629-E7638; PMID:27837024), a sequence encoding a 3xHA tag (to confirm expression with an HA antibody), the rabies virus glycoprotein gene GP (1572bp, UniProtKB accession No.P19462), a sequence encoding the Co1 peptide (Co1 peptide: SFHQLPARSPLP (sequence number 43), a peptide that improves antigen recognition by M cells involved in intestinal immunity; Kim et al. 2010, J Immunol. 185(10):5787-95; PMID:20952686), β-tubulin gene terminator (200 bp downstream including the termination codon of the β-tubulin / CMN263C gene), URA Cm-GsThe selection marker and downstream of the CMD185 gene (the sequence from 28 bp downstream of the stop codon to 880 bp) are arranged in the same order. The latter half and downstream sequence of CMD184C and downstream of the CMD185 gene are necessary for inserting a DNA fragment downstream of CMD184C by homologous recombination. The APCC promoter is necessary for constitutive expression of Chl-TP-HA-GP-Co1 (Watanabe et al 2011, J Gen Appl Microbiol. 57(1):69-72; PMID:21478650). URA Cm-Gs The selection marker is necessary to select transformants with Chl-TP-3HA-GP-Co1 inserted (Imamura et al. 2010, Plant Cell Physiol. 51(5):707-17; PMID:20375110), and can also be used to increase the number of copies of the gene and increase protein expression (Fujiwara et al. 2013, PloS One 8(9):e73608; PMID:24039997).
[0110] To construct the plasmid pD184-APCCp-Chl-TP-HA-GP-Co1, the following DNA fragments (1), (2), (3) and (4) were prepared. (1) Plasmid pD184-APCCp-EGFP-URA Cm-Gs (pQE80 (SEQ ID NO: 32), the latter half of CMD184C (SEQ ID NO: 33), APCC promoter (SEQ ID NO: 34), EGFP (SEQ ID NO: 35), β-tubulin terminator (SEQ ID NO: 36), URA Cm-Gs The DNA sequence of the portion excluding EGFP was amplified by PCR using the primers [#13APCC(-1)R / #14bT3'(+1)], which contain a selection marker (sequence number 44) and a DNA sequence downstream of the CMD185 gene (sequence number 38); Fujiwara et al. 2013, PLoS One. 8(9):e73608; PMID:24039997) as a template. (2) The DNA sequence of Chl-TP (sequence number 45) was amplified by PCR using the genomic DNA of C. merolae 10D as a template and the primer set [#15SecA(1)Fapcc / #16SecA(390)R-linker-ha]. (3) 3xHA (SEQ ID NO: 46) was amplified by PCR using the plasmid DNA containing it, pBSb-THA (Ohnuma et al. 2008, Plant Cell Physiol. 49(1):117-20; PMID:18003671), as a template and the primer set [#17HA(1)F / #18HA(90)R]. (4) The GP ORF was chemically synthesized (sequence number 40) in accordance with the codon usage frequency of C. merolae, and this was used as a template to amplify by PCR using the primer set [#19GP(1)Fha / #20Co1-GP(1680)Rbt].
[0111] The DNA fragments (1), (2), (3), and (4) were mixed and fused using the In-Fusion® HD Cloning Kit (product code: 639648, TAKARA) to obtain pD184-APCCp-EGFP-URA Cm-Gs The Chl-TP, 3xHA, and rabies virus glycoprotein ORF were inserted to replace the EGFP portion of pD184-APCCp-Chl-TP-3HA-GP-bt-URA. After the infusion reaction, the plasmid was amplified by introducing it into E. coli competent cells and named pD184-APCCp-Chl-TP-3HA-GP-bt-URA. Cm-Gs Next, using this as a template and primers [#11D184(1200)F / #12D184(+1400)R], a DNA fragment was amplified by PCR in which the latter half of the CMD184C gene (1200bp-2773bp of the gene ORF and the downstream 25bp including the stop codon), the APCC promoter, Chl-TP, 3xHA, GP, Co1 peptide, β-tubulin terminator, URACm-Gs selection marker, and the downstream of the CMD185C gene (the base sequence from the 28th to 1440bp) were linked. This DNA fragment was introduced into a uracil-requiring C. merolae strain M4 (Minoda et al. 2004, Plant Cell Physiol. 45(6):667-71; PMID:15215501) by the PEG method (Ohnuma et al. 2008, Plant Cell Physiol. 49(1):117-20; PMID:18003671), and selected on uracil-free MA2 solid medium to obtain a Chl-TP-3HA-GP-Co1 expressing strain.
[0112] (Evaluation of proteasomal degradation of Chl-TP-3HA-GP-Co1 protein) The ChlTP-sfGFP-HA-GP-Co1 expressing strain of C. merolae prepared as described above (hereinafter referred to as the “Chl-TP-3HA-GP-Co1 expressing strain”) and the wild-type strain (WT) as a negative control were each subcultured in 60 mL of MA2 medium in an Erlenmeyer flask at a cell density of OD750 = 0.2 and incubated under light irradiation (50 μmol m -2 s -1 ) and cultured at 40°C for 2 days with a gyratory rotation. Next, 20 mL of the culture medium of each strain was transferred to two Erlenmeyer flasks. To one of the two Erlenmeyer flasks, the proteasome inhibitor MG-132 was added to a final concentration of 100 μM to inhibit proteasome-mediated protein degradation (MG-132(+)) (Nishida et al 2005; Mol Biol Cell. 16(5):2493-502; PMID:15772156). To the other Erlenmeyer flask, 40 μL of DMSO, the solvent for MG-132, was added as a control (MG-132(-)). Expression of ChlTP-sfGFP-HA-GP-Co1 protein was confirmed by immunoblotting, and the effect of proteasome inhibition was verified by comparing the band patterns. Anti-HA antibody (clone 16B12, product code: 901503, Biolegend) was used to detect the ChlTP-sfGFP-HA-GP-Co1 protein.
[0113] The results of immunoblotting are shown in Figure 4. No difference in the band pattern of ChlTP-sfGFP-HA-GP-Co1 protein was observed between MG-132(-) and MG-132(+), indicating that ChlTP-sfGFP-HA-GP-Co1 protein was not degraded by the proteasome.
[0114] (Analysis of intracellular localization of ChlTP-sfGFP-HA-GP-Co1 protein) To analyze the intracellular localization of ChlTP-sfGFP-HA-GP-Co1 protein, the Chl-TP-3HA-GP-Co1 expressing cells were cultured for 2 days at 40°C under light irradiation in the absence of MG-132, fixed, and immunofluorescently stained with anti-HA antibody.
[0115] The results of immunofluorescence staining are shown in Figure 5. The signal from the anti-HA antibody indicated that the ChlTP-sfGFP-HA-GP-Co1 protein was localized in the chloroplast (between the thylakoids in the central part and the envelope membrane). The image (PC) in Figure 5(A) is a phase contrast microscope image showing the outline of the cell, the image (Chl) in Figure 5(B) is an autofluorescence image of the chloroplast, and the image (anti-HA) in Figure 5(C) is an immunofluorescence stained image using the anti-HA antibody. The localization of the ChlTP-sfGFP-HA-GP-Co1 protein detected by the anti-HA antibody in the chloroplast can be confirmed.
[0116] The sequences of the primers used in Examples 1 and 2 are shown in Table 1.
[0117] [Table 1]
[0118] [Example 3] (Administration to mice expressing GAPDH-GP-sfGFP) GAPDH-GP-sfGFP expressing strains were cultured at 1.3 × 10 8The cells were suspended in 300 mM glucose solution (isotonic solution) to a concentration of 1.5 cells / mL (OD750=4), and 250 μL of the suspension was delivered directly to the stomach of a mouse (ICR strain) using a sonde. After 0, 0.5, and 1.0 hours, the stomach, upper part of the small intestine, and lower part of the small intestine were excised, and each organ was suspended in 1 mL of 300 mM glucose solution. After centrifuging the suspension, the supernatant was collected and subjected to an ELISA assay for sfGFP, and the absorbance at 450 nm was measured.
[0119] The results of measuring the relative concentration of sfGFP in each organ (absorbance at 450 nm by ELISA assay) are shown in Table 2. sfGFP was hardly detected in the stomach, but was detected in the small intestine immediately after administration. This result indicates that the cells of the algae migrated from the stomach to the intestine immediately after administration, and ruptured in the intestine without rupturing in the stomach.
[0120] [Table 2]
[0121] [Example 4] (Feeding mice with alginate-solidified diet containing sfGFP expressing strain) C. merolae 10D cells (sfGFP expressing strain) that were labeled by expressing sfGFP in the cytoplasm (Sumiya et al. 2014, PLoS One. 9(10):e111261; PMID:25337786) were mixed with a commercially available diet (CLEA Rodent Diet CE-2, CLEA Japan, Inc.) and solidified with alginic acid as follows to prepare a feed sample. The sfGFP expression strain was suspended in 27 mL of 300 mM glucose solution (isotonic solution) (OD750=4), which was centrifuged at 3,000 g for 10 minutes, and the precipitated cells were collected. The sfGFP expression strain cells and 1.12 g of commercial feed (CE-2) were suspended in 10 mL of 2.5% sucrose solution containing 1% sodium alginate. The suspension was then dropped into a 10% calcium chloride solution to obtain an alginate-solidified feed sample containing the sfGFP expression strain and commercial feed. The content of the sfGFP expression strain in the feed sample was 4.6 mg wet weight / g (80-110 mg per grain). The mice (ICR strain) were allowed to freely consume the feed samples for 4 hours, and then were kept in a normal condition. Four, eight, 24, and 48 hours after the start of intake, the stomach, intestines, upper small intestine, and lower small intestine of the mice were excised. Each of the excised organs was suspended in a 300 mM glucose solution, centrifuged at 1,000 g, and the supernatant was collected and used as a sample for measuring the extracellular concentration of sfGFP. After collecting the supernatant, an equal amount of distilled water (DW) was added to the collected supernatant to resuspend the precipitate, and centrifuged at 1,000 g, and the supernatant was collected and used as a sample for measuring the intracellular concentration of sfGFP. The amount of sfGFP in the sample for measuring the extracellular concentration and the sample for measuring the intracellular concentration were quantified using a commercially available ELISA kit (GFP ELISA kit; cat no. ab171581, abcam), and were defined as the extracellular concentration and the intracellular concentration, respectively.
[0122] The results of measuring the relative concentration of sfGFP in each organ (absorbance at 450 nm by ELISA assay) are shown in Table 3. Both the extracellular and intracellular concentrations of sfGFP were detected at higher concentrations in the small intestine than in the stomach. Furthermore, the sfGFP concentration was higher in the lower part of the small intestine than in the upper part, and the ratio of the intracellular concentration to the extracellular concentration also increased. This result indicates that the cells of the algae burst in the small intestine and that sfGFP was taken up by the small intestinal cells.
[0123] [Table 3]
[0124] [Example 5] (Administration experiment and serum collection) The control suspension group was administered 1.3 × 10 8 The cells were suspended in 300 mM glucose solution (isotonic solution) to a concentration of 1.5 cells / mL (OD750 = 4), and 300 μL of the suspension was delivered directly to the stomach of mice (ICR strain; 3 individuals) using a probe. The same amount was orally administered six times every other week, and serum was collected two weeks after the final administration.
[0125] The "suspension administration group" consisted of 1.3 × 10 Chl-TP-3HA-GP-Co1 expressing strain (C. merolae ChlTP-sfGFP-HA-GP-Co1 protein expressing strain). 8 The cells were suspended in 300 mM glucose solution at a concentration of 1.5 cells / mL (OD750 = 4), and 300 μL of the suspension was delivered directly to the stomach of four mice (ICR strain) using a probe. The same amount was orally administered six times every other week, and serum was collected two weeks after the final administration.
[0126] As the "alginic acid solidified feed group", 27 mL of 300 mM glucose solution (OD750 = 4) in which the Chl-TP-3HA-GP-Co1 expression strain (C. merolae ChlTP-sfGFP-HA-GP-Co1 protein expression strain) was suspended was centrifuged at 3,000 g for 10 minutes, and the precipitated cells were collected. The cells of the Chl-TP-3HA-GP-Co1 expression strain and 1.12 g of commercial feed (CE-2) were suspended in 10 mL of 2.5% sucrose solution containing 1% sodium alginate. Next, this suspension was dropped into a 10% calcium chloride solution to obtain an alginic acid solidified feed sample containing the Chl-TP-3HA-GP-Co1 expression strain and commercial feed. The content of the Chl-TP-3HA-GP-Co1 strain was 4.6 mg wet weight / g (80 to 110 mg per grain). The mice (ICR strain; 4 mice) were allowed to freely consume the feed samples and then kept in a normal condition. The mice were fed the feed samples every other week for 6 times, and serum was taken 2 weeks after the final feeding.
[0127] (Evaluation of anti-GP protein antibody production) The production of anti-GP protein antibodies was confirmed by immunoblotting. First, to fuse a 6x histidine tag sequence to the amino terminus of the GP protein of rabies virus, the ORF of the GP gene was cloned into the pQE80 vector (containing a 6x histidine tag sequence, product code: 32923, QIAGEN) to create a plasmid. This plasmid was introduced into E. coli to express a 6x histidine tag fused GP protein (protein size: approximately 50 kDa). This was concentrated using a nickel column (product code: 17531901, GE Healthcare). Next, the 6x histidine tag fused GP protein concentrate was separated by electrophoresis using the SDS-PAGE method. The protein was transferred from the gel after electrophoresis to a polyvinylidene fluoride (PVDF) membrane (product code: IPVH00010, Merck). This was immersed in a dilution of serum collected from each mouse individual and incubated at room temperature for 1 hour. Serum dilution was prepared by diluting serum with Tris buffer (pH 7.5, containing 0.1% Tween 20) at 1:500. The presence or absence of anti-GP protein antibodies in serum was judged based on the presence or absence of antibody reaction to the GP protein located at approximately 50 kDa.
[0128] (result) The results of the immunoblot are shown in Figure 6. In the serum dilutions of mice 1, 2, and 3 in the negative control "control administration group (liquid)," no band was detected at approximately 50 kDa, which is the molecular weight size of the rabies GP protein (Figure 6(C)). In contrast, a band was detected at approximately 50 kDa in mice 2, 3, and 4 in the "alginate-solidified feed administration group" (Figure 6(A)) and mice 3 and 4 in the "suspension administration group" (Figure 6(B)). This result demonstrated that mice administered a suspension of C. merolae expressing rabies GP protein or alginate-solidified feed produced anti-GP protein antibodies.
[0129] (Consideration) In mouse 2 of the "control suspension administration group," a band smaller than the predicted size of the 6×histidine-tagged GP protein was detected. This is thought to be due to a nonspecific reaction of the antibody of that mouse to the E. coli-derived protein contained in the 6×histidine-tagged GP protein concentrate, unrelated to administration of the GP protein.
[0130] A series of examples confirmed that antigenic proteins properly introduced using the acid-resistant cells used in the present invention can be delivered to the upper part of the small intestine and beyond. It was also confirmed that antigenic proteins can be delivered to the target site in the same way when the acid-resistant cells into which the antigenic proteins of the present invention have been introduced are mixed into feed in a form that can be used in normal livestock and aquaculture. Furthermore, it was confirmed that the antigenic proteins delivered in this way activate the intestinal immune system, thereby producing antibodies in the blood.
Claims
1. A drug delivery composition comprising acid-resistant cells encapsulating a drug.
2. The drug is localized in a sac-like membrane structure of the acid-resistant cells. The drug delivery composition of claim 1.
3. The drug delivery composition according to claim 2 , wherein the sac-like membrane structure is at least one selected from the group consisting of an exogenous liposome, a cell membrane, and a cell organelle.
4. The drug delivery composition according to claim 3 , wherein the organelle is at least one selected from the group consisting of mitochondria, chloroplasts, endoplasmic reticulum, vacuoles, cell nuclei, peroxisomes, and Golgi apparatus.
5. The drug delivery composition according to any one of claims 1 to 4, wherein the drug is at least one selected from the group consisting of a low molecular weight compound, a peptide, a protein, and a nucleic acid.
6. The drug delivery composition according to any one of claims 1 to 5, wherein the drug is an intestinal acting drug.
7. The drug delivery composition according to any one of claims 1 to 6, wherein the drug is an immunogenic drug.
8. The drug delivery composition according to any one of claims 1 to 7, wherein the acid-resistant cells are cells that undergo cell rupture at a pH of 7 or higher.
9. The drug delivery composition according to any one of claims 1 to 8, wherein the acid-resistant cells are cells that are resistant to acidic conditions of pH 1 to 3.
10. The drug delivery composition according to any one of claims 1 to 9, wherein the acid-tolerant cells are cells of an alga belonging to the class Cyanidiophyceae.
11. A feed comprising the drug delivery composition according to any one of claims 1 to 10.
12. A pharmaceutical comprising the drug delivery composition according to any one of claims 1 to 10.
13. A food product comprising the drug delivery composition according to any one of claims 1 to 10.
14. Acid-resistant cells that encapsulate drugs within the cells.
15. An acid-resistant cell encapsulating a drug therein, the drug being localized in a sac-like membrane structure possessed by the acid-resistant cell.
16. The method comprises the step of introducing a gene encoding a fusion protein containing a peptide or protein as a drug and a peptide or protein localizing to a cell membrane or an organelle into an acid-resistant cell; A method for producing the acid-tolerant cells according to claim 15.
17. A drug carrier comprising acid-resistant cells.
18. The drug carrier according to claim 17, wherein the acid-resistant cells are cells that undergo cell rupture at a pH of 7 or higher.
19. The drug carrier according to claim 17 or 18, wherein the acid-resistant cells are cells that are resistant to acidic conditions of pH 1 to 3.
20. The drug carrier according to any one of claims 17 to 19, wherein the acid-tolerant cells are cells of an alga belonging to the class Cyanidiophyceae.
21. Acid-resistant cells containing exogenous substances.
22. The acid-tolerant cell according to claim 21 , wherein the exogenous substance is localized in a pouch-like membrane structure possessed by the acid-tolerant cell.
Citation Information
Patent Citations
Methods for oral / mucosal vaccination using recombinant yeast
JP2012508697A
Vaccine for oral administration
WO2006028214A1
